AFMD vs. TPST, LFVN, LPTX, RVPH, ANEB, HOOK, JAGX, CRVS, SLS, and CNTB
Should you be buying Affimed stock or one of its competitors? The main competitors of Affimed include Tempest Therapeutics (TPST), LifeVantage (LFVN), Leap Therapeutics (LPTX), Reviva Pharmaceuticals (RVPH), Anebulo Pharmaceuticals (ANEB), Hookipa Pharma (HOOK), Jaguar Health (JAGX), Corvus Pharmaceuticals (CRVS), SELLAS Life Sciences Group (SLS), and Connect Biopharma (CNTB). These companies are all part of the "pharmaceutical preparations" industry.
Affimed (NASDAQ:AFMD) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation, dividends, media sentiment and community ranking.
In the previous week, Tempest Therapeutics had 6 more articles in the media than Affimed. MarketBeat recorded 11 mentions for Tempest Therapeutics and 5 mentions for Affimed. Affimed's average media sentiment score of 1.52 beat Tempest Therapeutics' score of 0.65 indicating that Affimed is being referred to more favorably in the media.
Tempest Therapeutics has lower revenue, but higher earnings than Affimed. Tempest Therapeutics is trading at a lower price-to-earnings ratio than Affimed, indicating that it is currently the more affordable of the two stocks.
Affimed has a beta of 2.05, indicating that its stock price is 105% more volatile than the S&P 500. Comparatively, Tempest Therapeutics has a beta of -1.65, indicating that its stock price is 265% less volatile than the S&P 500.
30.8% of Affimed shares are owned by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are owned by institutional investors. 3.8% of Affimed shares are owned by company insiders. Comparatively, 3.3% of Tempest Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Affimed received 337 more outperform votes than Tempest Therapeutics when rated by MarketBeat users. Likewise, 69.92% of users gave Affimed an outperform vote while only 64.14% of users gave Tempest Therapeutics an outperform vote.
Tempest Therapeutics has a net margin of 0.00% compared to Affimed's net margin of -1,280.27%. Affimed's return on equity of -118.17% beat Tempest Therapeutics' return on equity.
Affimed currently has a consensus price target of $45.00, suggesting a potential upside of 782.35%. Tempest Therapeutics has a consensus price target of $25.00, suggesting a potential upside of 641.84%. Given Affimed's higher probable upside, research analysts clearly believe Affimed is more favorable than Tempest Therapeutics.
Summary
Affimed beats Tempest Therapeutics on 11 of the 16 factors compared between the two stocks.
Get Affimed News Delivered to You Automatically
Sign up to receive the latest news and ratings for AFMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AFMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
